BMS acquires Oncolys' festinavir HIV compound
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has entered into a definitive agreement with privately held Japanese biotech company Oncolys BioPharma to acquire exclusive worldwide rights to develop and commercialise festinavir (previously OBP-601 or Ed4T), a once-daily, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV.